CTOs on the Move

Tissuetech

www.biotissue.com

 
Bio-Tissue®, a subsidiary of TissueTech™, is the leader in regenerative biologic therapies and ocular hygiene solutions for eye care professionals. Established in 1997, Bio-Tissue® serves an unmet need for better surgical and therapeutic alternatives for helping eye care professionals heal ocular surface conditions, such as keratitis, recurrent corneal erosions, conjunctivochalasis dry eye, pterygium and dry eye. Eye care professionals understand that good medicine is based on good science. Bio-Tissue® prides itself on developing products that meet the highest clinical standards, are based on quality research and scientific data, and provide innovative solutions for a range of ocular surface and lid margin ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Tissuetech raised $15M on 06/22/2015
Tissuetech raised $55.2M on 04/14/2019

Similar Companies

Nava Health

Nava Health is a vertically integrated, tech-enabled healthcare practice that combines integrative, functional, preventive, and regenerative medicine to optimize health and increase longevity.

Capitol Drugs

Capitol Drugs is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Sherman Oaks, CA. To find more information about Capitol Drugs, please visit www.capitoldrugs.com

ReproTech

ReproTech is a company that specializes in long term cryostorage for fertility preservation through their nationwide network of partner Freezing Centers.

ClaimSecure Inc

ClaimSecure Inc is a Sudbury, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Berg LLC

BERG is a Boston-based biopharma company focused on taking a bold “back to biology” approach to therapeutic discovery using its unique AI-based Interrogative Biology® platform. This platform combines patient biology and AI-based analytics to engage the differences between healthy and disease environments. The patient’s own biology drives the platform’s results and guides us in the discovery and development of drugs, diagnostics and healthcare applications. Our platform utilizes patient population health data to bring actionable Patient IntelligenceTM to precision medicine applications. For patients this means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems. BERG has a robust product portfolio in oncology, endocrinology and neurology with mature assets in oncology entering mid and late stage trials. BERG is committed to improving the lives of patients through precision medicine made possible by our innovative platforms.